Post on 12-Apr-2017
Structure-based Design and Synthesis of Novel
Inhibitors of Hepatitis C Virus NS3 Helicase
An MPharm Degree Project in Medicinal Chemistry
Matthew Courtney-Smith
The Welsh School of Pharmacy
Cardiff University
2011
Declaration
This thesis is the result of my own investigation, except where otherwise stated. Other
sources are acknowledged by explicit references.
Word Count
………...........................................................................................
Signed
...................................................................................................
Dated
...................................................................................................
2
AcknowledgmentsI wish to express my gratitude to my supervisor, Dr. Andrea Brancale, whose knowledge,
assistance and encouragement have contributed greatly to my experience in a project I have
truly enjoyed. I would like to extend my thanks to all of Andrea’s colleagues in the Medicinal
Chemistry Department of The Welsh School of Pharmacy, not least Marcella Bassetto and Dr.
Antonio Ricci. Their kindness, and enthusiasm for chemistry is highly admirable, and I can
only hope this is reflected in my work. Special thanks of course go to my family, without
whom none of this would have been possible. Their love and belief is constant, and has
supported me both through life and my time at university(s). Finally, I must acknowledge
everyone at The Welsh School of Pharmacy for providing me not only with an opportunity to
learn, but also to do so amongst the best of friends. It has been a pleasure and a privilege to
share these memorable years with a group of great people; a time I will look back on forever
with happiness.
3
AbstractThe hepatitis C virus (HCV) is a small, enveloped positive-sense RNA virus responsible for the
infection of up to 170 million people worldwide. Current standard of care combination
therapy with pegylated interferon alfa and ribavirin is effective in less than 50 per cent of
cases, and has a severe associated side effect profile. For these reasons, there is an urgent
interest in the development of more potent and better-tolerated targeted therapies for
hepatitis C. The HCV NS3 helicase, which has an essential role in viral replication through the
unwinding of duplex nucleic acids, has been proposed as a promising orphan target, with no
drug candidates currently in clinical trials. Described herein are the structure-based design,
molecular docking, and synthesis of a novel series of inhibitors of the NS3 helicase.
A compound library of 112 potential inhibitors was designed based around the structural
modification of the symmetrical lead compound 1, which demonstrated modest antiviral
activity against subgenomic HCV replicon cell lines (EC50 = 8 μM). With the aim of improving
activity, the compounds were docked into the RNA binding site of the 3KQH crystallised NS3
helicase structure using GLIDE software, and the best ranked poses were screened by visual
inspection for interactions with key surface residues. Eight outstanding candidates were
selected for further development, and all were synthesised by a simple two-step reaction
scheme in good overall yields.
Of the proposed compounds, 13, 16, and 22 showed the most extensive interactions with the
RNA binding site, although they did not appear to associate with the crucial Trp501 residue,
which is understood to stack against the 3’-terminal base of the bound nucleic acid.
Compound 14 demonstrated clear potential, with binding both to Trp501 and Glu493, a key
residue of similar mechanistic importance. Despite a relatively low docking score, the
asymmetrical compound 17 was chosen for synthesis both due to its evident association with
the nearby Glu493 residue, and its clear superiority over other candidates in terms of
molecular weight.
Currently, the study is awaiting the results of HCV replicon and helicase enzymatic assays for
4
all eight synthesised compounds, which will determine the next stage of investigation. The
main priority will be the rational optimisation of the compound(s) showing greatest activity
to ultimately obtain a novel class of potent anti-HCV inhibitors.
Abbreviations and Definitions
ATP Adenosine triphosphate
GLIDE Grid-based ligand docking with energetics
HCV Hepatitis C virus
HIV Human immunodeficiency virus
HOBt Hydroxybenzotriazole
IRES Internal ribosome entry site
NMR Nuclear magnetic resonance
NS Non-structural protein
NTR Non-translated region
Peg-IFN-α Pegylated-interferon-alfa
RdRp RNA-dependent RNA polymerase
RNA Ribonucleic acid
SVR Sustained virological response
TBTU O-(Benzotriazol-1-yl)-N,N,N´,N´-tetramethyluronium tetrafluoroborate
TLC Thin layer chromatography
5
ContentsAbstract...................................................................................................................... 4
Abbreviations and Definitions..................................................................................... 5
1 Introduction............................................................................................................. 7
1.1 The Hepatitis C Virus (HCV)…………………………………………………………………………. 7
1.1.1 HCV Background……………………………………………………………………….... 7
1.1.2 Current Treatments…………………………………………………………………….. 7
1.1.3 HCV Genome, Life Cycle, and Strategies for Inhibition………………... 8
1.2 An Orphan Drug Target……………………………………………………………………………….. 12
1.2.1 HCV NS3 Helicase……………………………………………………………………….. 12
1.2.2 Structure of HCV NS3 Helicase……………………………………………………. 12
1.2.3 Mechanism of HCV NS3 Helicase Action……………………………………… 14
1.2.4 HCV NS3 Helicase as a Drug Target……………………………………………… 15
1.3 Molecular Docking…………………………………………………………………………………...... 17
1.4 Research Objectives……………………………………………………………………………………. 18
2 Results and Discussion.............................................................................................. 19
2.1 Structure-based Design: A Novel Compound Library…………………………………... 19
2.2 Compounds Selected for Chemical Synthesis…………………………………………...... 23
2.3 Docking Studies…………………………………………………………………………………………… 25
2.4 Chemical Synthesis……………………………………………………………………………………….34
2.5 Conclusions and Future Work……………………………………………………………………... 41
4 Experimental Section................................................................................................ 42
4.1 Molecular Modelling........................................................................................ 42
4.2 General Synthetic Procedures.......................................................................... 42
4.3 Synthesis of N-(bromoalkyl)-arenesulfonamides............................................. 43
4.4 Synthesis of N,N'-(alkylarenesulfonamide)-piperazines...................................44
4.5 Synthesis of N-(propyl-2-naphthalenesulfonamide)-piperidine.......................45
4.6 Synthesis of 3-(arenesulfonamide)-propanoic acids........................................ 45
6
4.7 Synthesis of N,N'-(3,3'-(piperazine-1,4-diyl)bis(3-oxopropane-3,1-diyl))-
diarenesulfonamides.............................................................................................. 46
5 References................................................................................................................ 48
7
1. Introduction1.1 The Hepatitis C Virus (HCV)
1.1.1 HCV Background
The Hepatitis C Virus (HCV), a small, enveloped RNA virus belonging to the Hepacivirus genus
of the Flaviviridae family,1,2 was first identified in 1989 as the agent responsible for the
majority of post-transfusion non-A, non-B hepatitis cases.3 It is estimated that HCV is
prevalent amongst up to 3% of the global population, corresponding to 170 million infected
people worldwide.4 Few patients show early signs of acute infection, such as malaise or
jaundice, but the majority – up to 80% – will progress to chronic disease beyond six months.5
This persistence is partly due to the virus's unique ability to evade the host immune
response. In around 40% of cases, chronic hepatitis C leads to cirrhosis,6 which remains the
primary reason for liver transplantation in the developed world.7 A significant proportion of
sufferers will go on to develop hepatocellular carcinoma, and overall prognosis is poor.
There are six known genotypes of HCV, which share up to 70% nucleotide sequence similarity
and may be further divided into more closely related subtypes. Genotypes 1a, 1b and 3a,
which have spread widely as a result of infected blood transfusions, transplantation or
needle-sharing, now contribute the most infections to the Western world.8 The virus
circulates in affected individuals as a series of variants, often referred to as quasispecies. The
existence of quasispecies appears to be an overriding factor in viral persistence, as chronic
hepatitis C patients tend to show greater genetic complexity than those with self-limiting
infection.9
1.1.2 Current Treatments
Historically, treatment of chronic hepatitis C has been restricted to the use of an
immunomodulatory interferon alongside the broad-spectrum antiviral ribavirin. Interferons
work by increasing the expression of major histocompatibility complex proteins to allow the
immune system to more efficiently recognise presenting viral antigens, as well as enhancing
the function of natural killer cells and macrophages.10 Ribavirin, a synthetic guanosine
nucleoside analogue, exerts its antiviral activity by several mechanisms, including depletion
of the intracellular pool of GTP, and direct incorporation of its metabolites into viral RNA to
8
interrupt mRNA synthesis.11,12 The non-specific combination of interferon-alpha (IFN-α) with
ribavirin proved to be relatively ineffective, with barely 40% of patients showing signs of any
lasting benefit.13 Studies showed that by increasing the interferon dosage, and limiting its
clearance rate, it would be possible to maximise its therapeutic effectiveness. This soon led
to the introduction of pegylated interferon-alpha (peg-IFN-α),14,15 which offered a modest
improvement due to its prolonged half-life.
Currently, the only recommended treatment is combination therapy with peg-IFN-α and
ribavirin, usually lasting for six to twelve months.16,17 The primary aim is a 'sustained
virological response', or SVR, which is defined as an undetectable serum HCV RNA level
twenty-four weeks after the discontinuation of therapy.18 Despite recent progress, and the
promise of improved forms of ribavirin, treatment efficacy remains strictly limited, and varies
considerably with genotype. Clinical studies with both forms of peg-IFN-α (2a and 2b) have
consistently shown an SVR in just 40-50% of patients with genotype 1 infection, and 70-80%
of those with genotypes 2 and 3.18-20 Current treatments are also limited by a relatively
severe side effect profile, particularly in those affected by other diseases, such as HIV.18-20,22
Influenza-like symptoms, including fatigue, headache, pyrexia and insomnia, are especially
common, while more severe psychiatric disorders – mainly depression-related events – can
also be a problem. Furthermore, there have been several reports of neutropenia, haemolytic
anaemia, and thrombocytopenia, which have necessitated the immediate dose reduction or
complete withdrawal of therapy. For these reasons, there is an urgent interest in the
development of more effective and better-tolerated targeted therapies for hepatitis C.23
1.1.3 HCV Genome, Life Cycle, and Strategies for Inhibition
The cloning of the HCV genome in 1989,3 combined with recent advances in replicon
models,24 has helped us to characterise the viral life cycle, and identify opportunities for drug
development. The HCV genome is a single-stranded, positive-sense RNA molecule of ~ 9600
bp in length, which includes a large open reading frame (ORF) encoding for a 3000 amino
acid polyprotein.24 Translation of the HCV codon is initiated by a 5' non-translated region
(NTR), which acts as an internal ribosome entry site (IRES) to allow the 40S ribosomal subunit
to bind directly at the start of the ORF. The function of the 3' NTR is less well understood, but
is thought to be involved in minus-strand priming essential to viral replication. The precursor
9
polyprotein is post-translationally cleaved by host and viral proteases to form three structural
proteins (the core nucleocapsid protein, and the two envelope proteins, E1 and E2), a
putative ion channel-forming protein (p7), and six non-structural proteins (NS2, NS3, NS4A,
NS4B, NS5A, and NS5B).18,25,26
Figure 1. The HCV genome and its encoded proteins
Although the exact functions of all the non-structural proteins are yet to be fully elucidated,
researchers are aware that each step in the HCV life cycle represents a potential target for
anti-viral activity. Rapid progress in the treatment of HIV infection is seemingly leading the
way, as therapies target the inhibition of key viral enzymes. Protease inhibitors, for example,
have been of proven benefit in the treatment of HIV infection, contributing to a more than
80% reduction in AIDS-related mortality.27 Pharmaceutical companies are now focusing on
replicating this success in the treatment of hepatitis C.
HCV possesses two proteolytic enzymes: the zinc-dependent NS2/3 metalloprotease, which
catalyses the cleavage of NS2 from the polyprotein, and the NS3/4A serine protease, which
sequentially cleaves the remaining four junctions. To date, NS2/3 has been largely
overlooked as an antiviral target due to obscurities in the cleavage process,28 though novel
models for precise identification of protein function, and isolation of the enzyme catalytic
domain, have led to increasing optimism for the future. The NS3/4A protease is a somewhat
more attractive target,29 and as such several inhibitors have reached clinical trials. The first
was BILN-2061, or ciluprevir, which demonstrated a transient but significant and rapid
10
response in viral decline amongst patients infected with HCV genotype 1.30 Unfortunately,
trials were ended prematurely due to its significant cardiotoxicity.31 Side effects have also
contradicted the benefits of other similar inhibitors, such as boceprevir (SCH503034) and
telaprevir (VX-950).32,33
Figure 2. Structures of the NS3/4A protease inhibitors boceprevir and telaprevir
The NS5B RNA-dependent RNA polymerase (RdRp), which is key to viral replication, is
another good anti-HCV target. It is a viral-specific enzyme with no corresponding host-cell
homologues. Several novel inhibitors have progressed to clinical development including
IDX184, a once daily, oral HCV nucleotide polymerase inhibitor based on Idenix’s proprietary
liver targeting technology.35 Furthermore, recent work at The Welsh School of Pharmacy by
McGuigan et al. has identified a novel ‘Protide’ nucleoside analogue, INX-189,36 which has
shown great promise in early phase clinical trials. The results of a phase 1b trial in Genotype
1 naive HCV patients are eagerly anticipated,37 with U.S. company Inhibitex seeking to gain
marketing authorisation for INX-189 within the foreseeable future. This would be an
important milestone in the introduction of specific anti-HCV therapies.
Figure 3. Structure of the NS5B RNA-dependent RNA polymerase inhibitor INX-189
11
Boceprevir (Schering) Telaprevir (Vertex)
The first HCV protein to be crystallised was the portion of NS3 that acts as a helicase.38
However, thus far no drug candidates have progressed to clinical development, perhaps due
to uncertainties in its mechanism of action. Although its exact physiochemical role is still
unclear, NS3 helicase is clearly essential to viral replication and as such represents a
promising orphan target for the development of novel inhibitors of HCV.
12
1.2 An Orphan Drug Target
1.2.1 HCV NS3 Helicase
The HCV non-structural protein 3 (NS3) fulfils two distinct enzymatic functions. The N-
terminal hosts a serine protease, responsible for post-translational polyprotein processing,
while the 450 C-terminal amino acid residues constitute an RNA helicase domain.39 This NS3
helicase was the first HCV protein to be crystallised,38 and was shown almost 20 years ago to
hydrolyse ATP to catalyse the unwinding of duplex RNA or DNA. Although its precise role is as
yet unclear, helicase activity is understood to be essential for HCV replication. As such, HCV
RNA with mutations inactivating the NS3 helicase is unable to replicate in both in vivo
chimpanzee models and in subgenomic replicons.40
1.2.2 Structure of HCV NS3 Helicase
Sequence-based classification has placed the C-terminal domain of HCV NS3 into helicase
superfamily 2 (SF2), as described by Gorbalenya and Koonin,41 with a structure consisting of
three separate domains. Crystallised structures have shown that the most N-terminal domain
(domain 1) and the middle domain (domain 2) lie above the C-terminal domain (domain 3).
ATP binds at the cleft formed at the interface between domains 1 and 2, and RNA or DNA
binds between domain 3 and domains 1 and 2.42 Studies have identified a flexibly-linked
rotation of domain 2 relative to domains 1 and 3,43 which allows the NS3 helicase to exist in
two distinct conformations. In some structures, domain 2 faces away from the other
domains, confirming its existence in an “open” conformation, while some show domain 2
closer to its neighbours in a “closed” conformation. The enzyme must be in its closed state
for ATP hydrolysis to occur, and RNA binding can only take place in the open conformation.
Figure 4. Stereo ribbon diagram illustrating the
overall fold of the HCV NS3 helicase with bound
ssDNA. Domain 1 is coloured blue, domain 2 red
and domain 3 green. DNA is coloured yellow.38
The topologically similar domains 1 and 2
13
contain the seven conserved sequence motifs common to all related helicase enzymes.44
They lie in close proximity to each other around the bound ATP, suggesting an essential
involvement in its binding and hydrolysis, or the transfer of ATP-dependent energy to nucleic
acid unwinding. Site-directed mutagenesis studies have shown that mutations in motifs I to
VI impact the ability of the helicase to both hydrolyse ATP and unwind duplex nucleic
acids.45,46.
Domains 1 and 2 host two motifs that are conserved in all HCV isolates but not other similar
helicases. The first, as described by Lam et al.,47 is centred around an arginine residue
(Arg393), which is understood to clamp the helicase to the nucleic acid strand. The second
motif, or Phe-loop, connects two anti-parallel sheets between SF2 motifs 5 and 6.
The role of domain 3 is less well characterised, though it is clearly essential for NS3 helicase
activity as deletion of 97 amino acids from the C-terminus of NS3 inactivates the enzyme.
Site-directed mutagenesis has identified two critical residues: Trp501, which stacks against
the 3'-terminal base of the RNA strand,48 and Glu493, which repels nucleic acids from the
binding cleft whilst ATP is bound in the closed conformation.49
Figure 5. Key residues in the RNA binding cleft of the HCV NS3 helicase
14
1.2.3 Mechanism of HCV NS3 Helicase Action
The cycle of helicase activity begins as ATP is bound in the cleft between the two adjacent
domains 1 and 2.42 The subsequent break down (hydrolysis) of ATP into ADP and inorganic
phosphate releases energy to allow domain 2 to rotate away from domain 1.
The exact mechanism through which NS3 helicase unwinds double-stranded RNA is still the
subject of intense debate. Most theories consider the conformational switch to correlate
directly to movement of the enzyme along the nucleic acid. As domains 1 and 2 move along
the tracking strand, one nucleotide at a time, ATP binding and ADP release induce closing
and opening of the two domains, respectively. In its closed conformation, NS3 helicase has a
low affinity for RNA, compared with a high affinity in its open conformation. This means that,
as the enzyme cycles between these two states, it is able to sequentially grab and release the
RNA tracking strand in order to translocate and unwind the polynucleotide.
These changes can be visualised in the interactions between two highly conserved threonine
residues, Thr269 and Thr411, and RNA.50,51 In a crystal structure of NS3 helicase, isolated in
the absence of ATP, these particular residues bind to two RNA phosphates that are 3
nucleotides apart. Structures of similar SF2 helicases show that the closure of domains 1 and
2 upon ATP binding brings the equivalent threonines one nucleotide closer, evidencing the
bulk movement of the protein in a 3'-to-5' direction.
The “ratcheting inchworm” model proposed by Kim et al.38 considers the Trp501 residue of
domain 3 to act as a 3'-bookend, remaining stacked against the 3'-terminal base to maintain
the relative position of the nucleic acid fixed while domains 1 and 2 translocate. This
prediction is validated by site-directed mutagenesis studies, which confirm that HCV helicase
is unable to unwind RNA without a bulky aromatic amino acid at position 501.48 The residue
that acts as the analogous 5'-bookend is believed to be Val432.38,42 The suggested mechanism
for translocation and unwinding of a single base-pair is illustrated in Figure 6.
15
Figure 6. A schematic diagram illustrating the mechanism of translocation and unwinding of
a single base-pair by HCV NS3 helicase
Electrostatic analysis of the RNA binding site has identified a key ionisable residue, Glu493,
which must be protonated for the helicase to be optically active.49 This observation led to the
development of the “propulsion-by-repulsion” model for NS3 helicase activity, in which an
acidic patch on the protein surface provides the driving force for its translocation along the
nucleic acid strand.42 Negatively-charged RNA binds in the negatively-charged cleft and is
unable to exit the enzyme as it remains fixed in position by Trp501 and the Arg-clamp of
domain 2. This leads to the build-up of potential energy. As domain 2 rotates, it brings with it
the positively-charged Arg-clamp, thus attracting the negatively-charged phosphodiester
backbone of RNA, which moves free of the Trp501 bookend. The binding cleft then repels the
similarly-charged polynucleotide, which propels through the protein as the potential energy
is released.
1.2.4 HCV NS3 Helicase as a Drug Target
The HCV helicase represents an exciting prospect for the development of novel anti-viral
agents, but has often been overshadowed by work on the more prominent non-structural
proteins, such as the NS5B polymerase or NS3/4A protease.23 As we begin to understand its
mechanism of action, NS3 helicase is increasingly recognised as a crucial target for
inhibition,52 with the potential not only to directly halt viral replication but also to stimulate a
cellular antiviral response brought about by the expected build-up of non-associated duplex
RNA. Despite the wealth of structural information available for well over a decade, only a
small number of NS3 helicase inhibitors have thus far been reported.The possible strategies
of inhibition are highlighted in Figure 7 and summarised below.23
16
Inhibition of ATPase activity
Competitive inhibitionof RNA binding
Inhibition of unwinding through intercalation of
the RNA duplex
Figure 7. Strategies for Inhibition of HCV NS3 Helicase
i. Inhibition of ATPase Activity
As previously discussed, the ATPase cycle is required to provide the energy that drives
the protein along the length of polynucleotide.42 Examples of competitive ATPase
inhibitors to be tested include ribavirin 5’-triphosphate (RTP) and ribavirin 5’-
disphosphate (RDP). However, although these compounds showed good ATPase
activity in the low μM range, they failed to elicit a significant reduction in helicase
unwinding rate.23 This unfortunate phenomenon was mimicked by paclitaxel. More
recently, a number of halogenated benzimidazoles and benzotriazoles have shown
improved inhibition,53 while a new class of ring-expanded nucleoside (REN) analogues
have also limited helicase unwinding.
Figure 8. ATPase inhibitors: Structures of benzimidazole and benzotriazole derivatives53
To overcome the problem of partial inhibition, several allosteric mechanisms have
17
DRB (R = Cl)DRBB (R = Br)
DRBT (R = Cl) α-DMRB (R = Me) TRBT (R = Cl)TBBT (R = Br)
been investigated, whereby antagonists such as trifluoroperazine block accessibility to
the ATP-binding site in a non-competitive manner.54 Cytotoxicity remains an issue, as
compounds that inhibit ATPase activity may also disrupt analogous host cell
mechanisms.
ii. Inhibition of Unwinding through Intercalation of the RNA Duplex
Nucleic acid duplexes are more stable when bound with an intercalating agent,
requiring a greater amount of energy to unwind. Progress into the development of
RNA-modulators has been slow, however, with effective inhibitors such as epirubicin
and nogalamycin proving to be highly toxic and non-selective.55
iii. Competitive Inhibition of RNA Binding
A more selective mechanism for anti-HCV activity appears to be the competitive
inhibition of RNA binding, which directly correlates to a decrease in unwinding
activity. There are several important leads in this field including QU663, which was
discovered by Maga et al. through optimisation of a series of compounds known to
bind HIV reverse transcriptase at the non-nucleoside binding site.56 QU663
competitively inhibits HCV helicase-catalysed DNA unwinding independent of its
associated ATPase activity, with a Ki of 750 nm. Molecular docking studies suggest
this compound binds at the RNA binding site in place of the polynucleotide, with key
interactions with both Trp501 and Arg393.
Figure 9. Structure of the NS3 helicase RNA
binding inhibitor QU663
18
1.3 Molecular Docking
Since its introduction in the early 1980s, molecular docking has fast become established as
an important tool for drug lead discovery and optimisation.57 A common computational
strategy involves the virtual screening of large compound databases, where a docking
program is able to predict all possible complex structures for different ligands bound at the
target protein active-site. These complexes are then scored and ranked by binding energy,
and the best candidates (hits) are selected for further development.
Early approaches to docking, such as the original DOCK algorithm,58 were based simply on a
rigid shape-complementarity between ligand and receptor. It is now clear that rigid docking
is of limited practical use, as the vast majority of ligands tend to exist in a variety of flexible
conformations according to the orientation of peripheral groups and internal bond angles. To
overcome this issue, several incremental construction algorithms including FlexX have been
introduced to pre-generate a variety of low-energy ligand conformations prior to docking and
scoring.59-61 Further improvements, as seen in the docking program GLIDE,62 have allowed the
shape and properties of the receptor to be mapped onto a grid of fields with progressively
more accurate scoring of each docked ligand pose.
All molecular docking studies in this project are performed on GLIDE (grid-based ligand
docking with energetics) software,63 which is chosen for its proven robustness in binding-
mode prediction. It is able to perform a near exhaustive search of the positional,
orientational and conformational space available to the ligand, whilst retaining sufficient
computational speed to cover large compound libraries.62 Initial ligand conformations are
screened across the entire phase space to predict a number of low-energy poses, which are
further minimised by a standard molecular mechanics energy function in conjunction with a
distance-dependent dielectric model. The predicted poses are then ranked by binding affinity
by a composite scoring function (Emodel) based on the 'GlideScore' combined with the
ligand-receptor molecular mechanics interaction energy and ligand strain energy.
19
1.4 Research Objectives
RNA binding agents remain at the forefront of investigation into novel HCV NS3h inhibitors.
Previous screening studies at the Welsh School of Pharmacy have identified 1 as a compound
with modest antiviral activity.
Figure 10. Structure of Compound 1
Table 1. Inhibitory activity (μM) of 1 against a cell-based HCV replicon replication and b isolated HCV NS3 helicase enzyme
EC50 (μM) a IC50 (μM) b
Compound 1 8 50
These data provide proof-of-concept in that 1 clearly has an inhibitory effect on viral
replication, although effective concentrations in the high micromolar range suggests
relatively low potency compared with other anti-HCV agents.
This report proposes the design and synthesis of a novel series of potential HCV NS3 helicase
inhibitors, based around the systematic variation of the structure of 1. With the aim of
enhancing potency, and increasing selectivity for the helicase enzyme, a small library of
newly designed compounds will be evaluated by docking simulation using GLIDE.63 The best
ranked poses will then be subject to visual inspection, with the consideration of specific
interactions with the active-site, focusing on the key residues of NS3 helicase action
previously described. The most promising compounds will be selected for synthesis and all
synthesised compounds will be tested in HCV replicon tissue culture and NS3 helicase
enzymatic assays.
20
2 Results and Discussion2.1 Structure-based Design: A Novel Compound Library
A series of potential NS3 helicase inhibitors is proposed based around the structural
modification of the symmetrical lead compound 1 at three positions, as shown in Figure 11.
Figure 11. Sites of Lead Compound Modification
The majority of substituents at A retain the aromatic ring (with the exception of a simple
methyl control group), as this is thought to interact with the key Trp501
residue of the
helicase enzyme. Direct replacement of the chlorine atom provides the para-substituted
methyl-, trifluoromethyl-, cyano-, nitro- and methoxybenzene derivatives, while a number of
dimethoxy- variations are also considered. The naphthalene, quinoline, and quinazoline
products are speculated to further enhance the aromaticity of the molecule.
At B, the linker chain is both shortened and extended (to 2C and 4C respectively) to
investigate its effects in coordinating the functional groups at the receptor site. For instance,
it would be desirable to find the most appropriate chain length to bring the aromatic group
into close proximity with the interacting Trp501
residue. Whilst a simple alkyl linker remains
flexible, allowing a multitude of conformations in the active-site, it is also possible to
maintain chain rigidity, with the use of a peptide bond adjacent to the core piperazine. It
21
Modification of linker chain
Variation of end-chain substituent
B
remains to be seen what effect this will have on the binding affinity.
It is important to note that modifications at A and B are consistent on either side of the
molecule, which retains its symmetry as a result. Molecules with dissimilar groups bonded to
each piperazine nitrogen atom would be too difficult to synthesise, and therefore do not
represent realistic candidates for drug development. However, it can be possible to replace
the piperazine group at C with a piperidine group, thus yielding a mono-substituted
asymmetrical product.
The various structural modifications that determine a library of 112 possible novel
compounds are detailed in Table 2. These compounds were docked into the 3KQH HCV
protein structure using GLIDE 63 in its standard precision mode, and the best ranked results
were visually inspected for signs of promising interactions with the RNA binding site.
Table 2. Structural Modifications at Variable Positions A, B and C
A B C
22
23
2.2 Compounds Selected for Chemical Synthesis
Following molecular docking, eight outstanding candidates were selected from the
compound library for synthesis and further development. They were chosen according to a
system that combined both the GLIDE 63 docking score and a visual inspection of interactions
with certain key binding site residues. Ease of synthesis was also an important consideration.
The highly conserved aromatic residue, Trp501, is a prime target in the search for novel NS3
helicase inhibitors. Several reported compounds are known to interact with the RNA binding
cleft in the region of Trp501, possibly interfering with its role in stacking against the 3'-
terminal base of the nucleic acid strand.38,42 It is hypothesised that such interactions will
interrupt the cycle of helicase activity by rendering the tryptophan residue inert, allowing
RNA to move free independent of enzyme conformation. Consideration of the docking
results showed that several compounds formed clear associations with Trp501, particularly
through aromatic naphthalene and dimethoxybenzene groups at the terminal ends of the
symmetrical molecule. Along with those that bind to Val432, which is speculated to act as
the analogous 5'-terminal bookend,38 these compounds represent promising choices to
advance to synthesis.
Interactions with the key ionisable Glu493 residue are exploited by six of the eight selected
compounds, particularly through hydrogen bonds donated by the core heterocyclic ring.
Glu493 is thought to have a highly significant role in the helicase mechanism of RNA
unwinding, acting to repel the negatively-charged nucleic acid upon ATP binding.42,49 Potential
24
inhibitors aim to bind and deionise this glutamic acid residue, thus disintegrating the
proposed cycle of propulsion-by-repulsion along the RNA strand. A similar case is observed
for Arg393, the focal residue of the Arg-clamp in domain 2,47 which associates by hydrogen
bonding to a sulfonyl oxygen atom in several proposed compounds.
Associations with other proximal groups will act to further stabilise the positioning of the
compounds at the RNA binding site, but are of incomparable significance in terms of
mechanistic effects. A good proportion of the chosen compounds demonstrated interactions
with the RNA-binding Thr411 residue, which is considered to be a good target for anti-
helicase activity due to its high sequence conservation between isolates.50,51 This should
confer a good degree of selectivity for the chosen NS3 helicase active-site.
The selected compounds have been numbered according to synthetic reaction schemes 1
and 2. They comprise a logical SAR investigation, in that the end-chain substituent is varied
only between three structures – naphthalene, 2,5-dimethoxybenzene, and 3,4-
dimethoxybenzene – linked to a central piperazine ring by an alkyl chain consisting of two or
three carbon atoms. Note that no compounds with a four-carbon chain are included, since
they were far surpassed by the shorter chain analogues in terms of docking score and key
interactions. Whilst most compounds tend to exceed a molecular weight of 500, they
generally fulfil the Lipinski criteria for good pharmacokinetics. Dimethoxybenzene-
substituted compounds, for instance, demonstrate good aqueous solubility. Log P is
calculated based on the unprotonated product form; hence the true values may fall as the
amide nitrogen is protonated in its natural state. Compounds 22 and 23 remain
unprotonated due to the stabilisation effects of an electron-withdrawing carbonyl group
adjacent to the piperazine ring. 23 has a relatively low docking score of -5.65, but the
presence of two key interactions with Thr411 and Arg393 merits its further investigation. It
will be interesting to consider how peptide rigidity and loss of charge on the amide nitrogen
affects inhibitory activity.
Of the proposed compounds, 13, 16 and 22 showed the most extensive interactions with the
RNA binding site, and thus can be speculated to offer the most promise for in vitro
investigation. Conversely, these compounds did not seem to interact with the crucial Trp501
25
residue, which must surely be weighted in terms of importance to activity. For this reason,
compound 14 demonstrated clear potential, with binding both to Trp501 and the key Glu493
residue. 14 also has a relatively low log P, which is highly significant in terms of delivery to its
target site.
The inclusion of a mono-substituted piperidine ring appeared to be detrimental to
interactions at the RNA binding site. However, compound 17 has been chosen for synthesis
both due to its evident association with the nearby Glu493 residue and its clear superiority
over other candidates in terms of molecular weight.
2.3 Docking Studies
Tables 3 – 10 summarise the results of molecular docking studies in GLIDE,63 with the
protein-ligand interactions displayed alongside the important structural and chemical
properties of the relevant compounds.
It is important to note that docking is merely a predictive interpretation of the most likely
interactions at the binding site, hence visual inspection of ligand orientation amidst
surrounding residues remains integral to investigation. For this reason, the proximal Trp501
residue has been identified by the author as a possible site of interaction with compounds 15
– 17 (shown in brackets), despite not being reflected in the displayed results.
26
Table 3. Key properties of proposed compound (12)
Name N,N'-(diethyl-2-naphthalenesulfonamide)-piperazine
Structure
Molecular Weight 552.72
Log P 2.87
Docking Score -6.61
27
Protein-ligand Interactions
Key Interactions Trp501
Table 4. Key properties of proposed compound (13)
Name N,N'-(dipropyl-2-naphthalenesulfonamide)-piperazine
Structure
Molecular Weight 580.77
28
Log P 3.65
Docking Score -7.03
Protein-ligand Interactions
Key Interactions Glu493 Val432 Thr411 Arg393
Table 5. Key properties of proposed compound (14)
Name N,N'-(diethyl-2,5-dimethoxybenzenesulfonamide)-piperazine
Structure
29
Molecular Weight 572.76
Log P 0.60
Docking Score -6.63
Protein-ligand Interactions
Key Interactions Trp501 Glu493
Table 6. Key properties of proposed compound (15)
Name N,N'-(dipropyl-2,5-dimethoxybenzenesulfonamide)-piperazine
Structure
Molecular Weight 600.76
30
Log P 1.38
Docking Score -6.25
Protein-ligand Interactions
Key Interactions Glu493 Val432 (Trp501)
Table 7. Key properties of proposed compound (16)
Name N,N'-(diethyl-3,4-dimethoxybenzenesulfonamide)-piperazine
31
Structure
Molecular Weight 572.76
Log P 0.60
Docking Score -6.77
Protein-ligand Interactions
32
Key Interactions Glu493 Val432 Thr411 (Trp501)
Table 8. Key properties of proposed compound (17)
Name N-(propyl-2-naphthalenesulfonamide)-piperidine
Structure
Molecular Weight 332.47
Log P 2.99
Docking Score -5.02
33
Protein-ligand Interactions
Key Interactions Glu493 (Trp501)
Table 9. Key properties of proposed compound (22)
Name N,N'-(3,3'-(piperazine-1,4-diyl)bis(3-oxopropane-3,1-diyl))-dinaphthalene-2-sulfonamide
34
Structure
Molecular Weight 608.74
Log P 2.70
Docking Score -7.32
Protein-ligand Interactions
Key Interactions Glu493 Thr411 Arg393
Table 10. Key properties of proposed compound (23)
Name N,N'-(3,3'-(piperazine-1,4-diyl)bis(3-oxopropane-3,1-diyl))-di-2,5-dimethoxybenzenesulfonamide
35
Structure
Molecular Weight 628.72
Log P 0.43
Docking Score -5.65
Protein-ligand Interactions
Key Interactions Thr411 Arg393
2.4 Chemical Synthesis
Compounds 12 – 17 were synthesised by reaction scheme 1, involving two distinct SN2
mechanistic steps. All reactions were successful at the first attempt, with good product yields
36
in the range of 66 – 89 per cent. Since most products were isolated in sub-gram quantities,
apparatus error in calculation of mass may render these figures as underestimates.
Dimethoxybenzene-substituted products were simplest to purify, as they were fully soluble in
the solvent and hence were added in solution to the column. In contrast, naphthalene-
substituted products were relatively insoluble and had to be suspended in the solvent.
Compound 13 presented the most difficulty in the work-up, as the large particles formed
from the reaction were not suspended fully for the column. In retrospect, the acceptable
yield of 71 per cent could be improved drastically by refining the particle size prior to
purification. All products eluted well in low percentage methanol in dichloromethane,
although separation was less distinct when the process was attempted with ethyl acetate as
the organic solvent. Intermediate compounds were verified by 1H NMR spectroscopy alone,
while the purity of final products was confirmed by both 1H and 13C NMR. Replicon and
enzymatic assays required a minimum purity of 99 per cent, which was achieved in all cases.
Reaction Scheme 1a
a Reagents and conditions: (i) NEt3, Ch2Cl2, 10 min; (ii) piperazine, NaHCO3, EtOH, reflux, 24 h;
(iii) piperidine, NaHCO3, EtOH, reflux, 24 h.
Step (i): 64 Two equivalents of triethylamine were used: one to release the primary amine
from the ammonium salt to react by nucleophilic substitution (SN2), as shown
by the mechanism in Figure 12, and the second to neutralise the HCl formed
from the reaction.
37
Figure 12. SN2 Mechanism for Reaction Step (i)
Step (ii): 65 Two equivalents of sodium bicarbonate were used: one to deprotonate both
the monosubstituted and disubstituted products formed in the two-stage SN2
mechanism shown in Figure 13. The reactions were successful in that the
monosubstituted species could not be detected by 1H or 13C NMR, since the
reaction had been forced to completion by an excess of the sulfonamide.
Figure 13. Two-stage SN2 Mechanism for Reaction Step (ii)
Step (iii): 65 The monosubstituted piperidine product, formed from a similar SN2
mechanism, was deprotonated by one equivalent of sodium bicarbonate.
38
Figure 14. SN2 Mechanism for Reaction Step (iii)
Compounds 22 and 23 were synthesised by reaction scheme 2. Both carboxylic acid
intermediates were obtained successfully by step (iv) at the first attempt, with good yields
despite some difficulties in maintaining a consistent basic pH. Indeed, proton NMR confirmed
the presence of the product with minimal starting material remaining, allowing 20 and 21 to
be used as reactants for step (v). This proved to be the most challenging step of all the
chemical synthesis, with two failed attempts before achieving a pure product. The reasons
for this are detailed below. Ultimately, however, good product yields of 77 and 80 per cent
were obtained for 22 and 23 respectively.
Reaction Scheme 2a
a Reagents and conditions: (iv) β-alanine, NaOH, H2O, 20˚C, until pH 9 then rt, 1 h; (v)
piperazine, TBTU, N,N-Diisopropylethylamine, Ch2Cl2, rt, 5 h.
Step (iv): 66 One equivalent of 2M NaOH was used to deprotonate the carboxylic acid
39
group of β-alanine, freeing it into solution to react by the SN2 mechanism
indicated in Figure 15. The pH was monitored and 1M NaOH added to
maintain basic conditions at pH 9 to retain the product in solution.
Figure 15. SN2 Mechanism for Reaction Step (iv)
Step (v): 67 The reaction was initially trialled with dimethylformadide (DMF) as a solvent,
but problems in purification of the final compound necessitated a change in
procedure. The product tended to elute from the packed column stacked
alongside N-Hydroxybenzotriazole (HOBt). Better purification was achieved
with dichloromethane in place of DMF, and HOBt was removed from the
reaction to leave TBTU as the solitary peptide coupling reagent.
TBTU is understood to exist in two different isomeric forms, of which the
guanidinium isomer predominates.68 This equilibrium is shown in Figure 16.
Figure 16. Equilibrium Showing the Formation of the Reactive Guanidinium Coupling Agent
N,N-Diisopropylethylamine was used as a base to deprotonate the carboxylic
acid group prior to reacting. TBTU was then used as a coupling agent to form
peptide bonds between two equivalent carboxylate ions and a core piperazine
ring. Figure 17 shows the mechanism for the formation of the
40
monosubstituted species, while Figure 18 shows the addition of a second
carboxylate ion to form the final product.
Figure 17. Mechanism for the Formation of the Monosubstituted Species in Reaction Step (v)
Figure 18. Mechanism for the Formation of the Final Product in Reaction Step (v)
1H NMR Comment: It is interesting to note that, for both dimethoxybenzene- and
41
naphthalene-substituted products, the amino proton presents furthest
downfield with a three-carbon linker chain, and furthest upfield with
two carbons. The peptide-linked compounds 22 and 23 give an
intermediate amino proton shift.
It is also worth commenting that the 1H NMR spectrum for compound
16 does not fully resolve many of the characteristic peak splits, which
instead present as multiplets. However, since the peaks occur in a shift
pattern similar to other compounds, 16 has clearly been isolated in its
purified form.
Overall, NMR spectra are clear and unquestionable, and act to confirm
the purity of the eight final compounds.
42
Table 11. Structures of Compounds 2 - 17
Compound R Y Product Yield (%)
2 - -
3 - -
4 - -
5 - CH2 -
6 - C2H4 -
7 CH2 73
8 C2H4 88
9 CH2 86
10 C2H4 70
11 CH2 89
12 CH2 89
13 C2H4 71
14 CH2 67
15 C2H4 66
16 CH2 66
17 C2H4 75
Table 12. Structures of Compounds 18 - 23
Compound R1 Product Yield (%)
18 -
19 -
20 71
21 72
22 77
23 80
43
2.5 Conclusions and Future Work
Poor efficacy and tolerability of current treatments has necessitated the development of novel
specific therapies for Hepatitis C.23 The Hepatitis C Virus (HCV) NS3 Helicase enzyme was identified
as a promising orphan target for investigation, with no drug candidates currently in clinical trials.
Development of a lead compound with modest antiviral activity yielded a library of 112 potential
inhibitors, which were screened by molecular docking studies for interactions with key RNA
binding site interactions.
Based on the docking results, eight compounds were selected for synthesis and further
development. All proposed compounds were successfully synthesised in good overall yields, and
the study is currently awaiting the results of HCV replicon tissue culture and NS3 helicase
enzymatic assays, which will determine the next stage of investigation. Selectivity may need to be
confirmed through identification of mutation of the helicase enzyme in a resistant viral strain.
Nonetheless, the main priority will be the rational optimisation of the compound(s) showing
greatest activity to ultimately obtain a novel class of potent anti-HCV inhibitors.
44
3 Experimental Section3.1 Molecular Modelling
All molecular modelling studies were performed on a MacPro running Ubuntu using Molecular
Operating Environment (MOE) 69 2009.10 and GLIDE 63 as docking suite molecular modelling
software.
All the minimisations were performed with MOE until RMSD gradient of 0.05 Kcal mol-1 Å-1 with the
MMFF94x forcefield and the partial charges were automatically calculated.
Docking experiments were carried out using GLIDE in Standard Precision (SP) with the default
options. The output of GLIDE docking was visualised in MOE.
3.2 General Synthetic Procedures
General Information
All chemicals, reagents and solvents were purchased from Aldrich or purified by standard
techniques.
Thin Layer Chromatography
Silica gel plates (Merck Kieselgel 60F254) were used and were developed by the ascending method.
After solvent evaporation, compounds were visualised by irradiation with UV light at 254nm and
366nm.
Column Chromatography
Glass columns were slurry packed in the appropriate eluent under gravity, with Woelm silica (32-
63mm). Samples were applied as a concentrated solution in the same eluent. Fractions containing
the product were identified by TLC, combined and the solvent removed in vacuo.
The purified products were obtained by gradient elution beginning with a wash of 200 mL 100%
dichloromethane. Compounds 12, 14, 15, 16 and 17 eluted with 1% methanol, 22 with 2%
methanol, 13 with 3% methanol, and 23 with 5% methanol.
NMR Spectroscopy1H, 13C, DEPT NMR spectra were recorded on a Bruker AVANCE 500 spectrometer (500MHz and
75MHz respectively) and auto calibrated to the deuterated solvent reference peak. Chemical shifts
are given in relative to tetramethylsilane (TMS); the coupling constants (J) are given in Hertz. The
spectra were recorded in CDCl3 or DMSO at room temperature; TMS served as an internal standard
(δ = 0 ppm) for 1H NMR and CDCl3 was used as an internal standard (δ = 77.0 ppm) for 13C NMR.
45
3.3 Synthesis of N-(bromoalkyl)-arenesulfonamides 64
N-(2-bromoethyl)-2-naphthalenesulfonamide (7). 2-naphthalenesulfonyl chloride (2, 1000 mg,
4.42 mmol, 0.99 equiv) and 2-bromoethylammonium bromide (5, 1006 mg, 4.91 mmol, 1.1 equiv)
were dissolved in 8 mL dry dichloromethane under a nitrogen atmosphere. The mixture was
treated dropwise with 1.43 mL triethylamine under ice-cooling and then stirred for 5 min under
cooling. The reaction mixture was washed twice with 15 mL 2M hydrochloric acid and 15 mL
saturated sodium chloride solution. Evaporation of the organic solvent after drying over
magnesium sulphate gave the crude product, as a white powder (73% yield), which was used for
the following step without further purification. 1H NMR (CDCl3, 500 MHz): δ 8.48 (s, 1H), 8.00 (m,
2H), 7.95 (d, J = 7.9 Hz, 1H), 7.87 (dd, J1 = 8.6 Hz, J2 = 1.8 Hz, 1H), 7.67 (m, 2H), 5.16 (s, br, 1H), 3.44
(m, 4H).
N-(3-bromopropyl)-2-naphthalenesulfonamide (8). The procedure was similar to the procedure
for 7 except that 3-bromopropylammonium bromide (6, 1075 mg, 4.91 mmol, 1.1 equiv) was used.
Compound 8 was isolated as a white powder (88% yield). 1H NMR (CDCl3, 500 MHz): δ 8.48 (s, 1H),
8.00 (m, 2H), 7.95 (d, J = 7.9 Hz, 1H), 7.87 (dd, J1 = 8.6 Hz, J2 = 1.8 Hz, 1H), 7.67 (m, 2H), 4.85 (t, J =
6.4 Hz, 1H), 3.45 (t, J = 6.3 Hz, 2H), 3.20 (q, J = 6.4 Hz, 2H), 2.07 (m, 2H).
N-(2-bromoethyl)-2,5-dimethoxybenzenesulfonamide (9). The procedure was similar to the
procedure for 7 except that 2,5-dimethoxybenzenesulfonyl chloride (3, 700 mg, 2.96 mmol, 0.99
equiv) and 2-bromoethylammonium bromide (5, 673 mg, 3.29 mmol, 1.1 equiv) were dissolved in
5.6 mL dry dichloromethane. The mixture was treated dropwise with 0.96 mL triethylamine.
Compound 9 was isolated as a pale yellow oil (86% yield). 1H NMR (CDCl3, 500 MHz): δ 7.44 (d, J =
2.4 Hz, 1H), 7.10 (dd, J1 = 9.1 Hz, J2 = 2.8 Hz, 1H), 6.99 (d, J = 8.9 Hz, 1H), 5.55 (s, 1H), 3.97 (s, 3H),
3.82 (s, 3H), 3.37 (m, 4H).
N-(3-bromopropyl)-2,5-dimethoxybenzenesulfonamide (10). The procedure was similar to the
procedure for 9 except that 3-bromopropylammonium bromide (6, 719mg, 3.29 mmol, 1.1 equiv)
was used. Compound 10 was isolated as a white powder (70% yield). 1H NMR (CDCl3, 500 MHz): δ
7.45 (d, J = 2.9 Hz, 1H), 7.10 (dd, J1 = 9.0 Hz, J2 = 2.9 Hz, 1H), 7.00 (d, J = 8.9 Hz, 1H), 5.54 (s, br, 1H),
3.96 (s, 3H), 3.81 (s, 3H), 3.40 (t, J = 6.2 Hz, 2H), 3.20 (q, J = 6.1 Hz, 2H), 2.10 (m, 2H).
46
N-(2-bromoethyl)-3,4-dimethoxybenzenesulfonamide (11). The procedure was similar to the
procedure for 7 except that 3,4-dimethoxybenzenesulfonyl chloride (4, 900 mg, 3.80 mmol, 0.99
equiv) and 2-bromoethylammonium bromide (5, 866 mg, 4.23 mmol, 1.1 equiv) were dissolved in
7.2 mL dry dichloromethane. The mixture was treated dropwise with 0.96 mL triethylamine.
Compound 11 was isolated as a white powder (89% yield). 1H NMR (CDCl3, 500 MHz): δ 7.52 (dd, J1
= 8.4 Hz, J2 = 2.2 Hz, 1H), 7.36 (d, J = 2.2 Hz, 1H), 6.97 (d, J = 8.4 Hz, 1H), 4.96 (s, br, 1H), 3.97 (s,
3H), 3.96 (s, 3H), 3.41 (m, 4H).
3.4 Synthesis of N,N'-(alkylarenesulfonamide)-piperazines 65
N,N'-(diethyl-2-naphthalenesulfonamide)-piperazine (12). Compound 7 (766 mg, 2.44 mmol, 2.1
equiv) was dissolved in 4 mL EtOH and added dropwise to a solution of piperazine (100 mg, 1.16
mmol, 1 equiv) and NaHCO3 (205 mg, 2.44 mmol, 2.1 equiv) in 4 mL EtOH. The reaction mixture
was stirred under reflux for 24 h then dried under pressure. The precipitate obtained was
suspended in 50 mL ethyl acetate and washed with 50 mL water and three times with 50 mL
saturated sodium chloride solution. The organic phase was collected and dried under vacuum, and
the white powder (89% yield) purified by acidic gel column chromatography. 1H NMR (CDCl3, 500
MHz): δ 8.45 (s, 1H), 7.97 (t, J1 = 8.2Hz, J2 = 8.8 Hz, 2H), 7.92 (d, J = 8.1 Hz), 7.82 (dd, J1 = 8.7 Hz, J2 =
1.8 Hz), 7.66 (m, 2H), 5.22 (s, br, 1H), 3.01 (s, br, 2H), 2.37 (t, J = 5.8 Hz, 2H), 2.18 (s, br, 4H); 13C
NMR (CDCl3, 75 MHz): δ 137.5, 134.1, 132.1, 129.4, 129.2, 128.8, 128.6, 127.9, 127.7, 122.2, 55.5,
52.3 (x2), 39.2.
N,N'-(dipropyl-2-naphthalenesulfonamide)-piperazine (13). The procedure was similar to the
procedure for 12 except that compound 7 (640 mg, 1.95 mmol, 2.1 equiv), piperazine (80 mg, 0.93
mmol, 1 equiv) and NaHCO3 (164 mg, 1.95 mmol, 2.1 equiv) were used. Compound 13 was isolated
as a white powder (71% yield). 1H NMR (CDCl3, 500 MHz): δ 8.44 (s, 1H), 7.99 (m, 2H), 7.95 (d, J =
7.9 Hz, 1H), 7.83 (dd, J1 = 8.7 Hz, J2 = 1.8 Hz, 1H), 7.66 (m, 2H), 7.32 (s, br, 1H), 3.13 (t, J = 5.5 Hz,
2H), 2.46 (s, br, 6H), 1.66 (m, 2H); 13C NMR (DMSO, 75 MHz): δ 137.4, 134.1, 131.7, 129.3, 129.1,
128.6, 127.8, 127.5, 127.3, 122.2, 54.7, 52.4, 40.9 (x2), 26.0.
N,N'-(diethyl-2,5-dimethoxybenzenesulfonamide)-piperazine (14). The procedure was similar to
the procedure for 12 except that compound 9 (567 mg, 1.75 mmol, 2.1 equiv), piperazine (70 mg,
47
0.83 mmol, 1 equiv) and NaHCO3 (147 mg, 1.75 mmol, 2.1 equiv) were used. Compound 14 was
isolated as a white powder (67% yield). 1H NMR (CDCl3, 500 MHz): δ δ 7.47 (d, J = 3.1 Hz, 1H), 7.08
(dd, J1 = 9.0 Hz, J2 = 3.0 Hz, 1H), 6.96 (d, J = 9.1 Hz, 1H), 5.58 (t, J = 4.9 Hz, 1H), 3.92 (s, 3H), 3.83 (s,
3H), 2.98 (m, 2H), 2.42 (t, J = 5.6 Hz, 2H), 2.31 (s, 4H); 13C NMR (CDCl3, 75 MHz): δ 153.4, 150.3,
127.8, 120.4, 114.9, 113.7, 57.1, 56.1, 56.0, 52.6 (x2), 39.9.
N,N'-(dipropyl-2,5-dimethoxybenzenesulfonamide)-piperazine (15). The procedure was similar to
the procedure for 14 except that compound 10 (592 mg, 1.75 mmol, 2.1 equiv) was used.
Compound 15 was isolated as a white powder (66% yield). 1H NMR (CDCl3, 500 MHz): δ 7.47 (d, J =
3.1 Hz, 1H), 7.08 (dd, J1 = 8.9 Hz, J2 = 3.1 Hz, 1H), 7.00 (d, J = 8.9 Hz, 1H), 6.22 (s, br, 1H), 3.95 (s,
3H), 3.83 (s, 3H), 3.00 (t, J = 6.2 Hz, 2H), 2.55 (s, br, 6H), 1.71 (m, 2H); 13C NMR (CDCl3, 75 MHz): δ
153.4, 150.4, 128.0, 120.2, 114.9, 114.2, 57.3, 56.6, 56.0, 52.8, 40.8 (x2), 25.4.
N,N'-(diethyl-3,4-dimethoxybenzenesulfonamide)-piperazine (16). The procedure was similar to
the procedure for 13 except that compound 11 (632 mg, 1.95 mmol, 2.1 equiv) was used.
Compound 16 was isolated as a white powder (66% yield). 1H NMR (CDCl3, 500 MHz): δ 7.49 (m,
1H), 7.34 (m, 1H), 6.94 (m, 1H), 5.11 (s, br, 1H), 3.96 (m, 3H), 3.94 (m, 3H), 2.99 (s, br, 2H), 2.40 (m,
2H), 2.26 (s, br, 4H); 13C NMR (CDCl3, 75 MHz): δ 152.6, 149.2, 131.3, 121.0, 110.5, 109.7, 56.3,
56.2, 55.6, 52.4 (x2), 39.2.
3.5 Synthesis of N-(propyl-2-naphthalenesulfonamide)-piperidine 65
N-(propyl-2-naphthalenesulfonamide)-piperidine (17). The procedure was similar to the
procedure for 12 except that compound 8 (450 mg, 1.37 mmol, 1.1 equiv), piperidine (106 mg,
1.25 mmol, 1 equiv) and NaHCO3 (115mg, 1.37 mmol, 1.1 equiv) were suspended in 6 mL EtOH
before stirring. Compound 17 was isolated as a pale yellow oil (75% yield). 1H NMR (CDCl3, 500
MHz): δ 8.45 (s, 1H), 7.98 (m, 2H), 7.93 (d, J = 7.9 Hz, 1H), 7.86 (dd, J1 = 8.6 Hz, J2 = 1.8 Hz, 1H), 7.64
(m, 2H), 5.31 (s, 1H), 3.11 (t, J = 5.7 Hz, 2H), 2.34 (m, 6H), 1.63 (m, 6H), 1.48 (s, br, 2H); 13C NMR
(CDCl3, 75 MHz): δ 137.2, 134.7, 132.2, 129.3, 129.1, 128.5, 128.2, 127.9, 127.4, 122.4, 72.1, 59.0,
54.5, 53.4, 44.7, 26.0, 24.2, 23.6.
3.6 Synthesis of 3-(arenesulfonamide)-propanoic acids 66
3-(2-naphthalenesulfonamide)-propanoic acid (20). To partially dissolved β-alanine (500 mg, 5.62
48
mmol, 1 equiv) in distilled water (1.5 mL) was added a solution of 2.81 mL 2M NaOH, followed by
the portion-wise addition of 2-naphthalenesulfonyl chloride (2, 1782 mg, 7.87 mmol, 1.4 equiv).
The reaction mixture was vigorously stirred and a solution of 1M NaOH was added portion-wise to
maintain a pH of 9 at 20°C. After complete consumption of alkali, stirring was continued at rt for an
additional 1 h. Unreacted acid chloride was removed by filtration, and the reaction mixture was
acidified with 5M HCl at 0°C to pH 2. The aqueous solution with solid precipitate was stored in the
refrigerator overnight. The crystals were collected by filtration, washed with cold water and dried
to give the crude product as a white powder (71% yield), which was used for the following step
without further purification. 1H NMR (CDCl3, 500 MHz): δ 8.46 (s, br, 1H), 8.00 (m, 2H), 7.93 (m,
1H), 7.85 (m, 1H), 7.65 (m, 2H), 5.83 (s, br, 1H), 3.23 (s, br, 2H), 2.66 (m, 2H). 13C NMR (DMSO, 75
MHz): δ 171.9, 137.2, 134.0, 131.9, 129.4, 129.2, 128.7, 128.0, 127.7, 127.3, 122.2, 38.8, 33.8.
3-(2,5-dimethoxybenzenesulfonamide)-propanoic acid (21). The procedure was similar to the
procedure for 20 except that β-alanine (250 mg, 2.81 mmol, 1 equiv) was dissolved in 1 mL distilled
water, followed by 1.5 mL 2M NaOH and the portion-wise addition of 2,5-
dimethoxybenzenesulfonyl chloride (2, 931 mg, 3.93 mmol, 1.4 equiv). Compound 21 was isolated
as a white powder (72% yield). 1H NMR (CDCl3, 500 MHz): δ 7.47 (d, J = 3.0 Hz, 1H), 7.11 (dd, J1 =
9.0 Hz, J2 = 3.0 Hz, 1H), 7.00 (d, J = 8.9 Hz, 1H), 5.78 (t, J = 6.6 Hz, 1H), 3.95 (s, 3H), 3.84 (s, 3H), 3.21
(q, J = 6.1 Hz, 2H), 2.61 (t, J = 5.9 Hz, 2H). 13C NMR (DMSO, 75 MHz): δ 172.4, 152.3, 150.2, 128.2,
119.5, 114.2 (x2), 56.4, 55.7, 38.7, 33.9.
3.7 Synthesis of N,N'-(3,3'-(piperazine-1,4-diyl)bis(3-oxopropane-3,1-diyl))-
diarenesulfonamides 67
N,N'-(3,3'-(piperazine-1,4-diyl)bis(3-oxopropane-3,1-diyl))-dinaphthalene-2-sulfonamide (22).
Compound 20 (200 mg, 0.72 mmol, 2.2 equiv) and TBTU (241 mg, 0.75 mmol, 2.3 equiv) were
suspended in 3 mL dry dichloromethane at rt. A solution of piperazine (28 mg, 0.33 mmol, 1 equiv)
and N,N-diisopropylethylamine (0.25 mL, 1.50 mmol, 4.6 equiv) in 1 mL dry dichloromethane was
added, and left stirring at rt for 5 h under a nitrogen atmosphere. The reaction mixture was diluted
with 20 mL dry dichloromethane and washed once with 30 mL 5% citric acid solution, once with 30
mL saturated bicarbonate solution, and once with 30 mL saturated sodium chloride solution. The
organic phase was collected and evaporation of the solvent after drying over magnesium sulphate
gave the crude product as a white powder (77% yield), which was purified by acidic gel column
49
chromatography. 1H NMR (CDCl3, 500 MHz): δ 8.45 (s, 1H), 7.99 (m, 2H), 7.94 (d, J = 7.8 Hz, 1H),
7.86 (dd, J1 = 8.7 Hz, J2 = 1.8 Hz, 1H), 7.66 (m, 2H), 5.59 (m, 1H), 3.51 (m, 2H), 3.28 (m, 4H), 2.54 (m,
2H); 13C NMR (DMSO, 75 MHz): δ 169.2, 137.5, 134.1, 131.7, 129.4, 129.1, 128.7, 127.8, 127.6,
127.4, 122.3, 44.6, 44.2, 40.8, 40.6.
N,N'-(3,3'-(piperazine-1,4-diyl)bis(3-oxopropane-3,1-diyl))-di-2,5-dimethoxybenzenesulfonamide
(23). The procedure was similar to the procedure for 22 except that compound 21 (120 mg, 0.42
mmol, 2.2 equiv) and TBTU (139 mg, 0.43 mmol, 2.3 equiv) were suspended in 4mL dry
dichloromethane. A solution of piperazine (16 mg, 0.19 mmol, 1 equiv) and N,N-
diisopropylethylamine (0.14 mL, 0.87 mmol, 4.6 equiv) in 1 mL dry dichloromethane was then
added. Compound 23 was isolated as a white powder (80% yield). 1H NMR (CDCl3, 500 MHz): δ
7.46 (d, J = 3.0 Hz, 1H), 7.09 (dd, J1 = 9.0 Hz, J2 = 3.0 Hz, 1H), 7.00 (d, J = 9.0 Hz, 1H), 5.92 (t, J = 6.1
Hz, 1H), 3.97 (s, 3H), 3.84 (s, 3H), 3.60 (m, 2H), 3.37 (m, 2H), 3.22 (q, J = 6.0 Hz, 2H), 2.55 (t, J = 5.5
Hz, 2H); 13C NMR (DMSO, 75 MHz): δ 168.9, 152.3, 150.2, 128.2, 119.5, 114.3, 114.2, 56.5, 55.8,
44.5, 44.2, 40.8, 40.5.
50
4 References(1) Lauer, G. M.; Walker, B. D. Hepatitis C virus infection. N. Eng. J. Med. 2001, 345, 41 – 52.
(2) Robertson, B.; Myers, G.; Howard, C.; Brettin, T.; Bukh, J.; Gaschen, B.; Gojo-bori, T.;
Maertens, G.; Mizokami, M.; Nainan, O.; Netesov, S.; Nishioka, K.; Shin, I. T.; Simmonds, P.;
Smith, D.; Stuyver, L.; Weiner, A. Classification, nomenclature, and database development for
hepatitis C virus (HCV) and related viruses: proposals for standardization. Arch. Virol. 1998,
143, 2493 – 2503.
(3) Choo, Q. L.; Kuo, G.; Weiner, A. J.; Overby, L. R.; Bradley, D. W. Isolation of a cDNA clone
derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989, 244, 359 –
362 .
(4) Lavancy, D. The global burden of hepatitis C. Liver International 2009, 29, 74 – 81.
(5) Hoofnagle, J. Course and outcome of hepatitis C. Hepatology 2002, 36, S21 – S29.
(6) Seeff, L. B. Natural history of chronic hepatitis C. Hepatology 2002, 36, S35 – S46.
(7) Carbone, M.; Neuberger, J. Liver transplantation for hepatitis C and alcoholic liver disease. J.
Transplant. 2010, 893893.
(8) Simmonds, P. Genetic diversity and evolution of hepatitis C virus – 15 years on. J. Gen. Virol.
2004, 85, 3173 – 3188.
(9) Kumar, D.; Malik, A.; Asim, M.; Chakravarti, A.; Das, R. H.; Kar, P. Influence of quasispecies on
virological responses and disease severity in patients with chronic hepatitis C. World J.
Gastroenterol. 2008, 14. 701 – 708.
(10) Tilg, H. New insights into the mechanisms of interferon alfa: an immunoregulatory and anti-
inflammatory cytokine. Gastroenterology 1997, 112, 1017 – 1021.
(11) Hoffman, W. P.; Herrmann, E.; Sarrazin, C.; Zeuzem, S. Ribavirin mode of action in chronic
hepatitis C: from clinical use back to molecular mechanisms. Liver International 2008, 28,
1332 – 1343.
(12) Leyssen, P.; Balzarini, J.; De Clercq, E.; Neyts, J. The predominant mechanism by which
ribavirin exerts its antiviral activity in vitro against flaviviruses and paramyxoviruses is
mediated by inhibition of IMP dehydrogenase. J. Virol. 2005, 79, 1943 – 1947.
(13) Scott, L. J.; Perry, C. M. Interferon-α-2b plus ribavirin : A review of its use in the management
of chronic hepatitis C . Drugs 2002, 62, 507 – 556.
(14) Cornberg, M.; Wedemeyer, H.; Manns, M. P. Treatment of chronic hepatitis C with PEGylated
interferon and ribavirin. Curr. Gastroenterol. Rep. 2002, 4, 23 – 30.
51
(15) Thomas, T.; Foster, G. Nanomedicines in the treatment of chronic hepatitis C – focus on
pegylated interferon alpha-2a. Int. J. Nanomedicine 2007, 2, 19-24.
(16) Manns, M. P.; Wedemeyer, H.; Cornberg, M. Treating viral hepatitis C: Efficacy, side effects,
and complications. Gut 2006, 55, 1350 – 1359.
(17) Strader, D. B.; Wright, T.; Thomas, D. L.; Seeff, L. B. Diagnosis, management and treatment of
hepatitis C. Hepatology 2004, 39, 1147 – 1171.
(18) Chevaliez, S.; Pawlotsky, J-M. Hepatitis C virus: Virology, diagnosis and management of
antiviral therapy . World J. Gastroenterol. 2007, 13, 2461 – 2466.
(19) Fried, M. W.; Shiffman, M. L.; Reddy, K. R.; Smith, C.; Marinos, G.; Gonçales, F. L. Jr.;
Haüssinger, D.; Diago, M.; Carosi, G.; Dhumeaux, D.; Craxi, A.; Lin, A.; Hoffman, J.; Yu, J.;
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Eng. J. Med.
2002, 347, 975 – 982.
(20) Manns, M. P.; McHutchison, J. G.; Gordon, S. C.; Rustgi, V. K.; Shiffman, M.; Reindollar, R.;
Goodman, Z. D.; Koury, K.; Ling, M-H.; Albrecht, J. K. Peginterferon alfa-2b plus ribavirin
compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a
randomised trial. Lancet 2001, 358, 958 – 965.
(21) Torres-Puente, M.; Cuevas, J. M.; Jimenez-Hernandez , N.; Bracho, M. A.; Garcia-Robles, I.;
Carnicer, F.; Del Olmo, J.; Ortega, E.; Moya, A.; Gonzales-Candelas, F. Hepatitis C virus and the
controversial role of the interferon sensitivity determining region in response to interferon
treatment. J. Med. Virol. 2008, 80, 247 – 253.
(22) Fried, M. W. Side effects of therapy of hepatitis C and their management. World J.
Gastroenterol. 2002, 36, S237 – S244.
(23) Gordon, C. P.; Keller, P. A. Control of hepatitis C: A medicinal chemistry perspective. J. Med.
Chem. 2005, 48, 1 – 20.
(24) Woerz, I.; Lohmann, V.; Bartenschlager, R. Hepatitis C virus replicons: Dinosaurs still in
business? J. Viral Hepatitis 2009, 16, 1 – 9.
(25) Suzuki, T.; Ishii, K.; Wakita, T.; Hepatitis C viral life cycle. Advanced Drug Delivery Reviews
2007, 59, 1200 – 1212.
(26) Bartenschlager, R.; Lohmann, V. Replication of hepatitis C virus. J. Gen. Virol. 2000, 81, 1631 –
1648.
(27) Wakita, T. HCV research and anti-HCV drug discovery: Toward the next generation . Advanced
Drug Delivery Reviews 2007, 59, 1196 – 1999.
52
(28) Welbourn, S.; Pause, A. The hepatitis c virus NS2/3 protease. Curr. Issues Mol. Biol. 2007, 9,
63 – 69.
(29) Kim, J. L.; Morgenstern, K. A.; Lin, C.; Fox, T.; Dwyer, M. D.; Landro, J. A.; Chambers, S. P.;
Markland, W.; Lepre, C. A.; O'Malley, E.T.; Harbeson, S. L.; Rice, C. M.; Murcko, M. A.; Caron,
P. R.; Thomson, J. A. Crystal structure of the hepatitis C virus NS3 protease domain
complexed with a synthetic NS4A Cofactor Peptide . Cell 1996, 87, 343 – 355.
(30) Hinrichsen, H.; Benhamou, Y.; Wedemeyer, H.; Reiser, M.; Sentjens, R. E.; Calleja, J. L.; Forns,
X. Erhardt, A.; Crönlein, J.; Chaves, R. L.; Yong, C-L.;Nehmiz, G.; Steinmann, G. Short-term
antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C
genotype 1 patients. Gastroenterology 2004, 127, 1347 – 1355.
(31) Vanwolleghem, T.; Meuleman, P.; Libbrecht, L.; Roskams, T.; De Vos, R.; Leroux-Roels, G.
Ultra-rapid cardiotoxicity of the hepatitis C virus protease inhibitor BILN 2061 in the
urokinase-type plasminogen activator mouse . Gastroenterology 2007, 133, 1144 – 1155.
(32) Poordad, F.; McCone, J. Jr.; Bacon, B. R.; Bruno, S.; Manns, M. P.; Sulkowski, M. S.; Jacobsen, I.
M.; Reddy, K. R.; Goodman, Z. D.; Boparai, N.; DiNubile, M. J.; Sniukiene, V.; Brass, C. A.;
Albrecht, J. K.; Bronowicki, J. P.; SPRINT-2 Investigators. Boceprevir for untreated chronic HCV
genotype 1 infection. N. Eng. J. Med. 2011, 364, 1195 – 1206.
(33) McHutchison, J. G.; Manns, M. P.; Muir, A. J.; Terrault, N. A.; Jacobson, I. M.; Afdhal, N. H.;
Heathcote, E. J.; Zeuzem, S.; Reesink, H. W.; Garg, J.; Bsharat, M.; George, S.; Kauffman, R. S.;
Adda, N.; Di Bisceglie, A. M.; PROVE3 Study Team. Telaprevir for previously treated chronic
HCV infection. N. Eng. J. Med. 2010, 362, 1292 – 1303.
(34) Kim, J.; Chong, Y. Understanding the RNA specificity of HCV RdRp: Implications for anti-HCV
drug discovery. Bull Korean Chem. Soc. 2006, 27, 59- 64.
(35) Zhou, X, J.; Pietropaolo, K.; Chen, J.; Khan, S.; Sullivan-Bolyai, J.; Mayers, D. Safety and
pharmacokinetics of IDX184, a liver-targeted nucleotide polymerase inhibitor of hepatitis C
virus, in healthy subjects . Antimicrobial Agents and Chemotherapy 2011, 55, 76 – 81.
(36) McGuigan, C.; Madela, K.; Aljarah, M.; Gilles, A.; Brancale, A.; Zonta, N.; Chamberlain, S.;
Verbnachio, J.; Hutchins, J.; Hall, A.; Ames, B.; Gorovits, E.; Ganguly, B.; Kolykhalov, A.; Wang,
J.; Muhammad, J.; Patti, J. M.; Henson, G. Design, synthesis and evaluation of a novel double
pro-drug: INX-08189. A new clinical candidate for hepatitis C virus. Bioorg. Med. Chem. Lett.
2010, 20, 4850 – 4854.
(37) Inhibitex. Study of the safety & PK of INX-08189 in chronically-infected HCV, treatment-naïve
53
subjects. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US).
2000- [cited 2011 Mar 20]. Available from: http://clinicaltrials.gov/show/NCT01250366
NLM Identifier: NCT00004451.
(38) Kim, J. L.; Morgenstern, K. A.; Griffith, J. P.; Dwyer, M. D.; Thomson, J. A.; Murcko, M. A.; Lin,
C.; Caron, P. R. Hepatitis C virus NS3 RNA helicase domain with a bound oligonucleotide: the
crystal structure provides insights into the mode of unwinding . Structure 1998, 6, 89 – 100.
(39) Lin, C.; Kim, J. L. Structure-Based mutagenesis study of hepatitis C virus NS3 helicase. J Virol.
1999, 73, 8798 – 8807.
(40) Lam, A. M. I.; Frick, D. N. Hepatitis C virus subgenomic replicon requires an active NS3 RNA
helicase . J. Virol. 2006, 80, 404 – 411.
(41) Gorbalenya, A. E.; Koonin, E. V. Helicases: amino acid sequence comparisons nd structure-
function relationships. Curr. Opinion in Structural Biology 1993, 3, 419 – 429.
(42) Frick, D, N. The hepatitis C virus NS3 protein: A model RNA helicase and potential drug
target . Curr. Issues Mol. Biol. 2007, 9, 1 – 20.
(43) Delagoutte, E.; Von Hippel, P. H. Helicase mechanisms and the coupling of helicases within
macromolecular machines. Part I : Structures and properties of isolated helicases . Quarterly
Reviews of Biophysics. 2002, 35, 431 – 478.
(44) Hall, M. C.; Matson, S. W. Helicase motifs: the engine that powers DNA unwinding. Mol.
Microbiol . 1999, 34, 867 – 877.
(45) Kim, D. W.; Kim, J.; Gwack, Y.; Han, J.H.; Choe, J. Mutational analysis of the hepatitis C virus
RNA helicase. J. Virol. 1997, 71, 9400–9409.
(46) Tai, C. L.; Pan, W. C.; Liaw, S. H.; Yang, U. C.; Hwang, L. H.; Chen, D. S. Structure-based
mutational analysis of the hepatitis C virus NS3 helicase. J. Virol. 2001, 75, 8289–8297.
(47) Lam, A. M. I.; Keeney, D.; Frick, D. N. Two novel conserved motifs in the hepatitis C virus NS3
protein critical for helicase action . J. Biol. Chem. 2003, 278, 44514 – 44524.
(48) Kim, J. W.; Seo, M. Y.; Shelat, A.; Kim, C. S.; Kwon, T. W.; Lu, H. H.; Moustakas, D. T.; Sun, J.;
Han, J. H. Structurally conserved amino acid W501 is required for RNA helicase activity but is
not essential for DNA helicase activity of hepatitis C virus NS3 protein. J. Virol. 2003, 77, 571
– 582.
(49) Frick, D. N.; Rypma, R. S.; Lam, A. M.; Frenz, C. M. Electrostatic analysis of the hepatitis C
virus NS3 helicase reveals both active and allosteric site locations. Nucleic Acids Res. 2004,
32, 5519 – 5528.
54
(50) Lin, C.; Kim, J. L. Structure-based mutagenesis study of hepatitis C virus NS3 helicase. J. Virol.
1999, 73, 8798 – 8807.
(51) Myong, S.; Bruno, M. M.; Pyle, A. M.; Ha, T. Spring-loaded mechanism of DNA unwinding by
hepatitis C virus NS3 helicase. Science 2007, 317, 512- 516.
(52) Belon, C. A.; Frick, D. N. Helicase inhibitors as specifically targeted antiviral therapy for
hepatitis C . Future Virol. 2009, 4, 277 – 293.
(53) Borowski, P.; Deinert, J.; Schalinski, S.; Bretner, M.; Ginalski3, K.; Kulikowski, T.; Shugar, D.
Halogenated benzimidazoles and benzotriazoles as inhibitors of the NTPase/helicase
activities of hepatitis C and related viruses . Eur J. Biochem. 2003, 270, 1645 – 1653.
(54) Kuang, W. F.; Lin, Y. C.; Jean, F.; Huang, Y. W.; Tai, C. L.; Chen, D. S.; Chen, P. J.; Hwang, L. H.
Hepatitis C virus NS3 RNA helicase activity is modulated by the two domains of NS3 and
NS4A. Biochem. Biophys. Res. Commun. 2004, 317, 211 – 217.
(55) Borowski, P.; Schalinski, S.; Schmitz, H. Nucleotide triphosphatase/helicase of hepatitis C
virus as a target for antiviral therapy. Antiviral Res. 2002, 55, 397 – 412.
(56) Maga, G.; Gemma, S.; Fattorusso, C.; Locatelli, G. A.; Butini, S.; Persico, M.; Kukreja, G.;
Romano, M. P.; Chiasserini, L.; Savini, L.; Novellino, E.; Nacci, V.; Spadari, S.; Campiani, G.
Specific targeting of hepatitis C virus NS3 RNA helicase. Discovery of the potent and selective
competitive nucleotide-mimicking inhibitor QU663. Biochemistry 2005, 44, 9637 – 9644.
(57) Jain, A. N. Scoring functions for protein-ligand docking. Curr. Protein Pept. Sci. 2006, 7, 407 –
420.
(58) Makino, J. A.; Skillman, G.; Kuntz, I. D. DOCK 4.0: search strategies for automated molecular
docking of flexible molecule databases. J. Comput.-Aided Mol. Des. 2001, 15, 411 – 428.
(59) Bursulaya, B. D.; Totrov, M.; Abagayan, R.; Brooks, C.L. Comparative study of several
algorithms for flexible ligand docking. J Comput.-Aided Mol. Des. 2003, 17, 755 – 763.
(60) Onodera, K.; Satou, K.; Hirota, H. Evaluations of molecular docking programs for virtual
screening. J. Chem. Inf. Model. 2007, 47, 1609-1618.
(61) Kramer, B.; Rarey, M.; Lengauer, T. Evaluation of the FlexX incremental construction
algorithm for protein-ligand docking. Proteins 1999, 37, 228 – 241.
(62) Friesner, R. A.; Banks, J. L.; Murphy, R. B.; Halgren, T. A.; Klicic, J. J.; Mainz, D. T.; Repasky, M.
P.; Knoll, E. H.; Shelley, M.; Perry, J. K.; Shaw, D. E.; Francis, P.; Shenkin, P. S. Glide: A new
approach for rapid, accurate docking and scoring. 1. Method and assessment of docking
accuracy. J Med Chem 2004, 47, 1739 – 1749.
55
(63) Glide, version 5.5, Schrödinger, LLC, New York, NY, 2009 http://schrodinger.com
(64) Tada, M.; Shijima, H.; Nakamura, M. Smiles-type free radical rearrangement of aromatic
sulfonates and sulfonamides: syntheses of arylethanols and arylethylamines. Org. Biomol.
Chem. 2003, 1, 2499 – 2505.
(65)
(66) Kotha, S.; Singh, K. Cross-enyne and ring-closing metathesis cascade: A building-block
approach suitable for diversity-oriented synthesis of densely functionalized
macroheterocycles with amino acid scaffolds. Eur. J. Org. Chem. 2007, 5909 – 5916.
(67)
(68) Carpino, L. A.; Imazumi, H.; El-Faham, A.; Ferrer, F. J.; Zhang, C.; Lee, Y.; Foxman, B. M.;
Henklein, P.; Hanay, C.; Mügge, C.; Wenschuh, H.; Klose, J.; Beyermann, M.; Bienert, M. The
uranium/guanidinium peptide coupling reagents: Finally the true uranium salts. Angew.
Chem. Int. Ed. Engl. 2002, 41, 441 – 445.
(69) Molecular Operating Environment (MOE). Chemical Computing Group, Inc. Montreal,
Quebec, Canada. http://www.chemcomp.com
NEED REFERENCES FOR REACTIONS STEPS (ii)/(iii) and (v)
56